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Purpose: To evaluate the effect of statin treatment on strut coverage after drug-
eluting stent (DES) implantation. Materials and Methods: In this study, 60 pa-
tients were randomly assigned to undergo sirolimus-eluting stent (SES) or biolim-
us-eluting stent (BES) implantation, after which patients were randomly treated 
with pitavastatin 2 mg or pravastatin 20 mg for 6 months. The degree of strut cover-
age was assessed by 6-month follow-up optical coherence tomography, which was 
performed in 52 DES-implanted patients. Results: The percentages of uncovered 
struts were 19.4±14.7% in pitavastatin-treated patients (n=25) and 19.1±15.2% in 
pravastatin-treated patients (n=27; p=0.927). A lower percentage of uncovered 
struts was significantly correlated with a lower follow-up low-density lipoprotein 
(LDL) cholesterol level (r=0.486; p=0.009) and a greater decline of the LDL cho-
lesterol level (r=-0.456; p=0.015) in SES-implanted patients, but not in BES-im-
planted patients. In SES-implanted patients, the percentage of uncovered struts 
was significantly lower among those with LDL cholesterol levels of less than 70 
mg/dL after 6 months of follow-up (p=0.025), but no significant difference in this 
variable according to the follow-up LDL cholesterol level was noted among BES-
implanted patients (p=0.971). Conclusion: Lower follow-up LDL cholesterol lev-
els, especially those less than 70 mg/dL, might have a protective effect against de-
layed strut coverage after DES implantation. This vascular healing effect of lower 
LDL cholesterol levels could differ according to the DES type.
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INTRODUCTION
Neointimal coverage over stent struts emerged as an important clinical issue after 
it was reported that incomplete strut coverage might be associated with the occur-
rence of late stent thrombosis following drug-eluting stent (DES) implantation.1-4 
Optical coherence tomography (OCT) is a useful tool that has excellent resolution 
for confirming neointimal stent strut coverage.5,6 Although several variables such 
as the implantation of sirolimus-eluting stents (SESs)7,8 and acute coronary syn-
drome9,10 were reported as risk factors for delayed strut coverage in previous OCT 
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also randomly allocated. Thus, four groups were created as 
follows: pitavastatin-N-BES group (12 patients), pitavas-
tatin-SES group (17 patients), pravastatin-N-BES group (18 
patients), and pravastatin-SES group (13 patients). Post-in-
tervention OCT examinations were performed for all pa-
tients immediately after DES implantation. Among 60 pa-
tients, 6-month follow-up angiography was not performed 
for three patients, the OCT catheter could not be passed 
through the lesion due to severe angulation in three pa-
tients, and there was poor image quality in two patients. 
Therefore, follow-up OCT evaluation was performed for 
52 patients as follows: pitavastatin-N-BES group (10 pa-
tients), pitavastatin-SES group (15 patients), pravastatin-N-
BES group (14 patients), and pravastatin-SES group (13 
patients) (Fig. 1). Blood samples to evaluate lipid profiles 
were obtained at the time of stent implantation and follow-
up angiography. All patients were clinically followed up 1, 
3, and 6 months after stent implantation.
Coronary intervention and quantitative coronary 
angiography analysis
All patients received at least 75 mg of aspirin and a loading 
dose of 300 mg of clopidogrel at least 12 h pre-interven-
tion. Unfractionated heparin was administered to maintain 
the activated clotting time at >250 s. All percutaneous coro-
nary interventions were performed according to current 
standard techniques. Post-intervention, dual antiplatelet 
therapy with aspirin 100 mg and clopidogrel 75 mg daily 
was prescribed for 12 months.
Quantitative coronary angiographic analysis was per-
formed before and after stent implantation as well as at fol-
studies, the relationship of specific medications (i.e., statins) 
with strut coverage is not fully understood. Statins are the 
most widely used lipid-lowering agents in patients with 
coronary artery disease. These drugs reduce inflammation 
and enhance endothelial function via pleiotropic effects.11 
Previous in vitro and animal studies reported that statins 
regulate the migration and proliferation of smooth muscle 
cells and control neointimal formation.12-15 However, there 
are no human data that assess the impact of statin treatment 
on strut coverage after DES implantation. Therefore, we 
conducted a randomized OCT study to evaluate the effect 
of statin treatment on DES strut coverage.
MATERIALS AND METHODS
Study design and patient enrollment
The present study consisted of subgroup analysis of a pre-
vious randomized OCT study16 and evaluated the impact of 
statin treatment on strut coverage. The previous OCT study 
was performed to compare strut coverage 6 months after 
Nobori biolimus-eluting stent (N-BES, Nobori®, Terumo 
Corporation, Tokyo, Japan; n=60) or SES (CypherTM, Cor-
dis Corp., Miami Lakes, FL, USA; n=60) implantation. 
The inclusion and exclusion criteria of the OCT study were 
provided in the previous report.16 Written informed consent 
was obtained from all participants, and the Institutional Re-
view Boards of our institute approved this study. In total, 
60 patients were enrolled in this study and randomly treated 
with pitavastatin 2 mg or pravastatin 20 mg, beginning on 
the day of stent implantation. Stenting (SES or N-BES) was 
Fig. 1. A flowchart of the study is shown. 
Refusal of follow-up angiogram in 3 patients; failure to perform 
follow-up optical coherence tomography in 3 patients; 
inappropriate image quality to analyze in 2 patients
Pitavastatin and biolimus-eluting 
stent (10 patients)
Biolimus-eluting stent 
(12 patients)
Pravastatin and biolimus-eluting 
stent (14 patients)
Biolimus-eluting stent 
(18 patients)
Pitavastatin and sirolimus-eluting 
stent (15 patients)
Sirolimus-eluting stent 
(17 patients)
Pravastatin and sirolimus-eluting 
stent (13 patients)
Sirolimus-eluting stent 
(13 patients)
Post-stent optical coherence tomography in all patients (n=60)
Follow-up optical coherence tomography at 6 months (n=52)
Pitavastatin-treated patients (n=29) Pravastatin-treated patients (n=31)
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dent’s t-test, or the Mann-Whitney U test. To avoid prob-
lems of sample size inflation and correlated data, only pa-
tients with one target lesion were included in the study. 
Cross-section analysis or strut-level analysis may not be 
straightforward due to the congregation of struts within each 
lesion in an interindividual manner. For this analysis, we 
performed multilevel regression model analysis. Specifical-
ly, the patient and lesion data were incorporated as random 
effect components using the lme4 package with R (http://
cran.r-project.org/web/packages/lme4/index.html).20 Pear-
son’s correlation analysis was performed to evaluate the re-
lationship between low-density lipoprotein (LDL) choles-
terol levels and the percentage of uncovered struts. Values 
of p<0.05 denoted statistical significance.
 
RESULTS
 
Baseline clinical and angiographic characteristics were simi-
lar between the pitavastatin-treated groups and pravastatin-
treated groups (Table 1). Significant reductions of LDL cho-
lesterol levels were observed at the 6-month follow-up time 
point (reduction: 24 mg/dL in the pitavastatin-treated group, 
p<0.001; 21 mg/dL in the pravastatin-treated group, p= 
0.003). Follow-up LDL cholesterols level less than 70 mg/dL 
were achieved in 10 patients (34.5%) in the pitavastatin-
treated group and 5 patients (16.1%) in the pravastatin-
treated group (p=0.101). OCT findings were also similar 
between pitavastatin-treated patients and pravastatin-treated 
patients (Table 2). The percentages of uncovered struts at 
the 6-month follow-up OCT were 19.4±14.7% in pitavas-
tain-treated patients (n=25) and 19.1±15.2% in pravastain-
treated patients (n=27) (p=0.927); conversely, the values 
were 23.3±16.6% in SES-implanted patients (n=28) and 
14.5±10.9% in BES-implanted patients (n=24) (p=0.026). 
In all of 52 patients, follow-up cholesterol levels of less 
than 70 mg/dL were associated with smaller percentages of 
uncovered struts (less than 70 mg/dL vs. 70 mg/dL or more; 
12.5±12.2% vs. 21.5±15.1%; p=0.058). Although the per-
centage of uncovered struts among SES-implanted patients 
was significantly lower in patients with follow-up LDL cho-
lesterol levels of less than 70 mg/dL (less than 70 mg/dL vs. 
70 mg/dL or more; 10.1±12.4% vs. 26.9±15.6%, respective-
ly; p=0.025), there were no significant differences in the 
percentage of uncovered struts among BES-implanted pa-
tients between those with follow-up LDL cholesterol levels 
of less than 70 mg/dL (14.6±12.7%) and those with levels 
low-up, using an offline quantitative coronary angiographic 
system (CASS system, Pie Medical Instruments, Maastricht, 
the Netherlands) in an independent core laboratory (Cardio-
vascular Research Center, Seoul, Korea). Using the guiding 
catheter for magnification and calibration, reference vessel 
diameters and the minimal luminal diameter were measured 
from diastolic frames in a single, matched view showing the 
smallest minimal luminal diameter. Late loss was defined 
as the difference between the post-procedure and follow-up 
minimal luminal diameters.
OCT imaging and cross-sectional analysis
Immediately and 6 months after the intervention, OCT of 
the target lesion was performed using a frequency-domain 
OCT system (C7-XR OCT imaging system, LightLab Im-
aging, Inc., St. Jude Medical, St. Paul, MN, USA). For this 
study, OCT cross-sectional images were generated at a ro-
tational speed of 100 frames per second while the fiber was 
withdrawn at a speed of 20 mm/s within the stationary im-
aging sheath. All OCT images were analyzed at a core lab-
oratory (Cardiovascular Research Center, Seoul, Korea) by 
analysts who were blinded to patient and procedural infor-
mation. 
Cross-sectional OCT images were analyzed at 0.2-mm 
longitudinal intervals. Stent and luminal cross-sectional ar-
eas (CSAs) were measured, and the neointimal hyperplasia 
(NIH) CSA was calculated as the stent area minus the lumi-
nal CSA. NIH thickness was measured as the distance be-
tween the endoluminal surface of the neointima and the 
strut.8 An uncovered strut was categorized as an NIH thick-
ness=0 μm.8 A malapposed strut was defined as a strut that 
had detached from the vessel wall by ≥130 μm (N-BES) or 
≥160 μm (SES).17,18 The percentage of uncovered or malap-
posed struts was calculated as the ratio of uncovered or 
malapposed struts to total struts in all OCT cross-sections. 
Intrastent thrombi were defined as irregular masses protrud-
ing into the lumen by more than 250 μm at the thickest 
point.19 
Statistical analysis
Statistical analysis was performed using Statistical Analysis 
System software (v. 9.1.3., SAS Institute, Cary, NC, USA) 
and R version 2.15.1 (R Development Core Team, Vienna, 
Austria, http://www.R-project.org). Categorical data were 
presented as numbers (%) and compared using the chi-
square or Fisher’s exact test. Continuous data were presented 
as the mean±SD and compared using a paired t-test, Stu-
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Table 1. Baseline Clinical and Angiographic Characteristics of the Pitavastatin-Treated Groups and Pravastatin-Treated Groups
Pitavastatin (n=29) Pravastatin (n=31) p value
Age, yrs 60.1±8.4 60.1±9.3 0.979
Male gender, n (%) 22 (75.9)  26 (83.9) 0.527
Hypertension, n (%) 14 (48.3)  12 (38.7) 0.455
Diabetes mellitus, n (%)   5 (17.2)  11 (35.5) 0.148
Current smoker, n (%)   6 (20.7)  10 (32.3) 0.311
Clinical presentation, n (%) 0.344
    Stable angina 24 (82.8)  21 (67.7)
    Unstable angina   3 (10.3)    8 (25.8)
    Acute myocardial infarction 2 (6.9)  2 (6.5)
Medication at hospital discharge, n (%)
    Aspirin 29 (100)  31 (100)
    Clopidogrel 29 (100)  31 (100)
    Beta-blocker 14 (48.3)  13 (41.9) 0.622
    Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker   8 (27.6)  14 (45.2) 0.158
    Calcium channel blocker 11 (37.9) 9 (29) 0.465
Initial laboratory profiles (mg/dL)
    Total cholesterol 185±41 168±55 0.208
    Low-density lipoprotein cholesterol 111±25 106±43 0.654
    High-density lipoprotein cholesterol 42±7 44±9 0.475
    Triglyceride 149±58 121±59 0.093
    High-sensitivity C-reactive protein     7.5±25.7   2.7±5.9 0.479
Follow-up laboratory profiles
    Total cholesterol (mg/dL) 156±34 159±25 0.655
    Low-density lipoprotein cholesterol (mg/dL)   86±26   86±18 0.894
    Low-density lipoprotein cholesterol level less than 70 mg/dL, n (%) 10 (34.5)    5 (16.1) 0.101
    Mean reduction of low-density lipoprotein cholesterol levels (mg/dL)  -24±27  -21±34 0.726
    High-density lipoprotein cholesterol (mg/dL) 43±6 42±9 0.611
    Triglyceride (mg/dL) 125±66 146±61 0.264
    High-sensitivity C-reactive protein (mg/dL)   3.1±6.7   1.2±1.0 0.278
Lesion and procedural characteristics
    ACC/AHA lesion class B2 or C, n (%) 13 (44.8)  15 (48.4) 0.782
    Vessel treated, left anterior descending artery, n (%) 16 (55.2)  18 (58.1) 0.821
    Type of drug-eluting stent implanted, n (%) 0.196
        Sirolimus-eluting stent 17 (58.6)  13 (41.9)
        Biolimus-eluting stent 12 (41.4)  18 (58.1)
    Stent diameter (mm)   3.18±0.32   3.18±0.30 0.993
    Stent length (mm) 20.5±7.0 20.1±6.3 0.806
    Maximal inflation pressure (atm) 16.3±2.9 16.9±2.8 0.644
Quantitative angiographic analysis (mm)
    Lesion length 18.9±7.1 17.6±6.3 0.465
    Pre-procedural reference vessel diameter   3.08±0.43   3.13±0.35 0.591
    Pre-procedural minimum luminal diameter   1.10±0.41   1.14±0.39 0.679
    Post-procedural minimum luminal diameter   2.76±0.41   2.86±0.33 0.311
    Acute gain   1.66±0.43   1.72±0.50 0.645
Follow-up
    Angiogram follow-up, n (%) 27 (93.1)  30 (96.8)
    Reference vessel diameter (mm)   2.89±0.26   2.98±0.48 0.369
    Minimal lumen diameter (mm)   2.54±0.42   2.67±0.48 0.285
    Late loss (mm)   0.22±0.38   0.19±0.36 0.785
ACC, American College of Cardiology; AHA, American Heart Association. 
Values are presented as n (%) or the mean±SD. 
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with the degree of LDL cholesterol reduction (r=-0.456; 
p=0.015) in SES-implanted patients but not in BES-implant-
ed patients.
DISCUSSION
Previous studies identified several factors that were associat-
ed with delayed strut coverage, such as SES implantation,7,8 
exceeding 70 mg/dL (14.4±10.5%; p=0.971). Fig. 2 pres-
ents the relationship of follow-up LDL cholesterol levels 
with strut coverage according to DES type. The percentage 
of uncovered struts was significantly correlated with fol-
low-up LDL cholesterol levels (r=0.486; p=0.009) in SES-
implanted patients but not in BES-implanted patients. Fig. 3 
presents the relationship of the degree of LDL cholesterol re-
duction with strut coverage according to DES type. The per-
centage of uncovered struts was also significantly correlated 
Table 2. Optical Coherence Tomography (OCT) Findings of the Pitavastatin-Treated Groups and Pravastatin-Treated Groups
Post-procedural Follow-up
Pitavastatin 
(n=29)
Pravastatin 
(n=30) p value
Pitavastatin 
(n=25)
Pravastatin 
(n=27) p value
Time to follow-up OCT, days - - - 181±14 194±34 0.074
Cross-section–level analysis
    Total No. of cross sections, n 2523 2654 - 2073 2279 -
    Mean stent cross-sectional area (mm2) 7.5±1.9 7.7±1.7 0.578 7.6±2.4   7.9±1.8 0.609
    Mean lumen cross-sectional area (mm2) 7.3±1.9 7.5±1.6 0.559 7.1±2.4   7.5±1.9 0.536
    Cross sections with any uncovered strut (%) - - - 55.7±32.0   60.9±24.3 0.513
    Cross sections with a ratio of uncovered to 
      total struts >0.3 (%) - - - 28.1±25.8   24.0±23.5 0.557
    Presence of intrastent thrombi, n (%) - - - 0 (0.0) 0 (0.0)
Strut-level analysis
    Total No. of analyzable struts, n 24484 25317 - 20223 21908 -
    Mean neointimal hyperplasia thickness, μm - - - 63.7±41.3   55.5±24.1 0.379
    Percentage of uncovered struts, % - - - 19.4±14.7   19.1±15.2 0.927
    Percentage of malapposed struts, % 2.7±3.7 3.3±8.2 0.685 0.6±1.4   0.8±3.0 0.760
    Both malapposed and uncovered struts, % - - - 0.5±1.3   0.7±3.0 0.753
Fig. 2. The relationships of the percentage of uncovered struts with follow-
up low-density lipoprotein (LDL) cholesterol levels are presented. Black 
and red dots represent biolimus-eluting stents and sirolimus-eluting stents, 
respectively.
Fig. 3. The relationships of the percentage of uncovered struts with the de-
gree of low-density lipoprotein (LDL) cholesterol level reduction are pre-
sented. Black and red dots represent biolimus-eluting stents and sirolimus-
eluting stents, respectively.
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for this finding is that the vascular healing response to 
statins or lower LDL cholesterol levels could be different ac-
cording to the type of DES. Compared to SESs, BESs have 
several different characteristics, including a bioresorbable 
polymer carrier (poly-lactic acid), as well as coating only on 
the abluminal stent surface to allow the direct release of li-
pophilic biolimus into the vessel wall.32,33 Differences in the 
polymer, drug, or drug-eluting period between BESs and 
SESs may influence the degree of strut coverage according 
to the LDL cholesterol-lowering effects of statins.
The present study has some limitations. First, although 
our study was designed as a randomized trial, the study pop-
ulation included a relatively small number of patients. We 
feel that a future study with a larger sample size would be 
needed to confirm our findings. However, our main findings 
could provide a clue, suggesting the possible relationship of 
lowering LDL cholesterol or use of statin with the vascular 
healing process. Second, all control groups received statin 
therapy. Therefore, we could not evaluate the effect of statin 
therapy on strut coverage by making comparisons with pa-
tients who did not receive statin treatment. However, a con-
trol group with no statin treatment would not be ethically 
justified in current clinical practice for DES-implanted pa-
tients with coronary artery disease.
In conclusion, this randomized study revealed a protec-
tive effect of statins against delayed strut coverage in SES-
implanted patients who achieved lower follow-up LDL 
cholesterol levels (especially less than 70 mg/dL). This vas-
cular healing effect of lower LDL cholesterol levels in-
duced by statins could be different according to the type of 
DES implanted.
ACKNOWLEDGEMENTS
This study was supported by a grant from the Korea Health-
care Technology R&D Project, Ministry for Health, Welfare 
& Family Affairs, Republic of Korea (nos. A085012 and 
A102064), a grant from the Korea Health 21 R&D Project, 
Ministry of Health & Welfare, Republic of Korea (no. 
A085136), and the Cardiovascular Research Center, Seoul, 
Korea.  
REFERENCES
1. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mecha-
acute coronary syndrome,9,10 the time interval between DES 
implantation and follow-up OCT,21 baseline high-sensitivity 
C-reactive protein levels,22 the stent diameter,23 diabetes mel-
litus,23 and American Heart Association/American College of 
Cardiology type B2/C lesions.23 Although several studies re-
vealed that statins have beneficial effects on both mature en-
dothelial cells and endothelial progenitor cells,24-27 there are 
no human data associating the use of statins with an accelera-
tion of strut coverage after DES implantation. Wang, et al.14 
demonstrated that atorvastatin pretreatment could accelerate 
both neointimal coverage and reendothelialization after SES 
implantation in a minipig model. Another animal study us-
ing a wire-mediated vascular injury model in mice reported 
that fluvastatin has protective effects against impaired reen-
dothelialization in sirolimus-treated arteries.24 The mecha-
nism by which statins protect against delayed vascular heal-
ing is linked to their ability to modulate smooth muscle cell 
proliferation and migration and increase circulating endo-
thelial progenitor cell counts.14,24 Experimental animal stud-
ies reported that each statin has different effects according 
to its water solubility.28,29
In this study, strut coverage was compared between pita-
vastatin-treated lesions and pravastatin-treated lesions, and 
we hypothesized that different statins may differentially af-
fect OCT-based strut coverage in DES-implanted lesions. 
Compared to pravastatin (a hydrophilic statin), pitavastatin 
(a fully synthetic lipophilic statin) has powerful efficacy 
comparable with that of atorvastatin and rosuvastatin.30,31 In 
the present study, a significant difference in strut coverage 
was not observed between the pitavastatin-treated groups 
and pravastatin-treated groups; however, greater DES strut 
coverage was significantly related with lower follow-up 
LDL cholesterol levels and greater reductions of LDL cho-
lesterol levels in SES-implanted lesions, but not in BES-
implanted lesions. 
These findings suggest that reducing LDL cholesterol lev-
els alone has a role in strut coverage after first-generation 
DES implantation. However, as mentioned previously, the 
primary mechanism by which statins modify the vascular 
healing process is considered to involve a pleotropic effect 
rather than a direct LDL cholesterol-lowering effect. There-
fore, this discrepancy might be explained by the fact that a 
lower LDL cholesterol level is one indicator of the intensity 
of the pleotropic effect of statins in the vascular healing pro-
cess. Additionally, the relationship between follow-up LDL 
cholesterol levels and strut coverage was not observed for 
next-generation DESs (i.e., BESs). A possible explanation 
Statin Treatment vs. Strut Coverage
Yonsei Med J   http://www.eymj.org   Volume 56   Number 1   January 2015 51
cle and endothelial cell proliferation and reduces neointima on a 
drug-eluting stent platform. Cardiovasc Res 2005;68:483-92.
16. Kim BK, Ha J, Mintz GS, Kim JS, Shin DH, Ko YG, et al. Ran-
domised comparison of strut coverage between Nobori biolimus-
eluting and sirolimus-eluting stents: an optical coherence tomog-
raphy analysis. EuroIntervention 2014;9:1389-97. 
17. Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Ma-
rio C. The influence of strut thickness and cell design on immedi-
ate apposition of drug-eluting stents assessed by optical coherence 
tomography. Int J Cardiol 2009;134:180-8.
18. Davlouros PA, Mavronasiou E, Xanthopoulou I, Karantalis V, 
Tsigkas G, Hahalis G, et al. An optical coherence tomography 
study of two new generation stents with biodegradable polymer 
carrier, eluting paclitaxel vs. biolimus-A9. Int J Cardiol 2012;157: 
341-6.
19. Kume T, Akasaka T, Kawamoto T, Ogasawara Y, Watanabe N, 
Toyota E, et al. Assessment of coronary arterial thrombus by opti-
cal coherence tomography. Am J Cardiol 2006;97:1713-7.
20. Doran H, Bates D, Bliese P, Dowling M. Estimating the multilevel 
Rasch model: with the lme4 package. J Stat Softw 2007;20:1-18.
21. Kim BK, Kim JS, Oh C, Ko YG, Choi D, Jang Y, et al. Major de-
terminants for the uncovered stent struts on optical coherence to-
mography after drug-eluting stent implantation. Int J Cardiovasc 
Imaging 2012;28:705-14.
22. Kim BK, Kim JS, Oh C, Ko YG, Choi D, Jang Y, et al. Impact of 
preprocedural high-sensitivity C-reactive protein levels on uncov-
ered stent struts: an optical coherence tomography study after 
drug-eluting stent implantation. Clin Cardiol 2011;34:97-101.
23. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishi-
da T, et al. Long-term follow-up of neointimal coverage of siroli-
mus-eluting stents--evaluation with optical coherence tomography. 
Circ J 2009;73:2300-7.
24. Fukuda D, Enomoto S, Shirakawa I, Nagai R, Sata M. Fluvastatin 
accelerates re-endothelialization impaired by local sirolimus treat-
ment. Eur J Pharmacol 2009;612:87-92.
25. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects 
of statins. Arterioscler Thromb Vasc Biol 2003;23:729-36.
26. Werner N, Priller J, Laufs U, Endres M, Böhm M, Dirnagl U, et 
al. Bone marrow-derived progenitor cells modulate vascular reen-
dothelialization and neointimal formation: effect of 3-hydroxy-
3-methylglutaryl coenzyme a reductase inhibition. Arterioscler 
Thromb Vasc Biol 2002;22:1567-72.
27. Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endo-
thelium and their contribution to neovascularization by mobiliza-
tion of endothelial progenitor cells. Coron Artery Dis 2004;15: 
235-42.
28. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, 
Ogata Y, et al. Usefulness of hydrophilic vs lipophilic statins after 
acute myocardial infarction: subanalysis of MUSASHI-AMI. Circ 
J 2007;71:1348-53.
29. Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors 
increase myocardial stunning in dogs. J Cardiovasc Pharmacol 
2000;35:256-62.
30. Saku K, Zhang B, Noda K; PATROL Trial Investigators. Random-
ized head-to-head comparison of pitavastatin, atorvastatin, and ro-
suvastatin for safety and efficacy (quantity and quality of LDL): 
the PATROL trial. Circ J 2011;75:1493-505.
31. Hayashi T, Yokote K, Saito Y, Iguchi A. Pitavastatin: efficacy and 
safety in intensive lipid lowering. Expert Opin Pharmacother 
2007;8:2315-27.
nisms of fatal late coronary stent thrombosis in humans. Circula-
tion 2003;108:1701-6.
2. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, 
et al. Pathological correlates of late drug-eluting stent thrombosis: 
strut coverage as a marker of endothelialization. Circulation 
2007;115:2435-41.
3. Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, 
Ikejima H, et al. Examination of the in vivo mechanisms of late 
drug-eluting stent thrombosis: findings from optical coherence to-
mography and intravascular ultrasound imaging. JACC Cardio-
vasc Interv 2012;5:12-20.
4. Won H, Shin DH, Kim BK, Mintz GS, Kim JS, Ko YG, et al. Op-
tical coherence tomography derived cut-off value of uncovered 
stent struts to predict adverse clinical outcomes after drug-eluting 
stent implantation. Int J Cardiovasc Imaging 2013;29:1255-63.
5. Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK, et 
al. Expert review document on methodology, terminology, and 
clinical applications of optical coherence tomography: physical 
principles, methodology of image acquisition, and clinical appli-
cation for assessment of coronary arteries and atherosclerosis. Eur 
Heart J 2010;31:401-15.
6. Lee SY, Hong MK. Stent evaluation with optical coherence to-
mography. Yonsei Med J 2013;54:1075-83.
7. Kim JS, Jang IK, Kim JS, Kim TH, Takano M, Kume T, et al. Op-
tical coherence tomography evaluation of zotarolimus-eluting 
stents at 9-month follow-up: comparison with sirolimus-eluting 
stents. Heart 2009;95:1907-12.
8. Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimi-
ya K, et al. Evaluation by optical coherence tomography of neo-
intimal coverage of sirolimus-eluting stent three months after im-
plantation. Am J Cardiol 2007;99:1033-8.
9. Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, et al. Different 
patterns of neointimal coverage between acute coronary syndrome 
and stable angina after various types of drug-eluting stents implan-
tation; 9-month follow-up optical coherence tomography study. 
Int J Cardiol 2011;146:341-6.
10. Kubo T, Imanishi T, Kitabata H, Kuroi A, Ueno S, Yamano T, et 
al. Comparison of vascular response after sirolimus-eluting stent 
implantation between patients with unstable and stable angina 
pectoris: a serial optical coherence tomography study. JACC Car-
diovasc Imaging 2008;1:475-84.
11. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the 
hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascu-
lar disease: a comprehensive review. Cardiol Rev 2010;18:298-
304.
12. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani 
A, et al. Effects of hydroxymethylglutaryl coenzyme A reductase 
inhibitor simvastatin on smooth muscle cell proliferation in vitro 
and neointimal formation in vivo after vascular injury. J Am Coll 
Cardiol 2000;35:214-21.
13. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi 
L, et al. Direct vascular effects of HMG-CoA reductase inhibitors. 
Atherosclerosis 1998;137 Suppl:S101-9.
14. Wang TJ, Yang YJ, Xu B, Zhang Q, Jin C, Tang Y, et al. Atorvas-
tatin accelerates both neointimal coverage and re-endothelializa-
tion after sirolimus-eluting stent implantation in a porcine model: 
new findings from optical coherence tomography and pathology. 
Circ J 2012;76:2561-71.
15. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, et 
al. Local statin therapy differentially interferes with smooth mus-
Yongsung Suh, et al.
Yonsei Med J   http://www.eymj.org   Volume 56   Number 1   January 201552
33. Ostojic M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N, et al. 
First clinical comparison of Nobori -Biolimus A9 eluting stents 
with Cypher- Sirolimus eluting stents: Nobori Core nine months 
angiographic and one year clinical outcomes. EuroIntervention 
2008;3:574-9.
32. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata 
H, et al. Randomized comparison of the Nobori Biolimus A9-elut-
ing coronary stent with the Taxus Liberté paclitaxel-eluting coro-
nary stent in patients with stenosis in native coronary arteries: the 
NOBORI 1 trial--Phase 2. Circ Cardiovasc Interv 2009;2:188-95.
